Press Releases
- December 10, 2008
Thallion Announces a Review of Strategic Alternatives
- November 18, 2008
Thallion Initiates Enrollment in Phase II Metastatic Melanoma Trial
- October 24, 2008
Thallion's TLN-4601 Inhibits Mutated K-RAS Signaling in Cancer Cells
- October 14, 2008
Thallion Announces 2008 Third Quarter Results
- October 9, 2008
Notice of Thallion Pharmaceuticals Fiscal 2008 Third Quarter Conference Call
- October 3, 2008
(This Press Release was issued by Caprion Proteomics Inc.) Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract
- September 25, 2008
Thallion Enrolls First Patient in TLN-4601 Phase II Trial - Receives FDA approval to initiate TLN-4601 trial in U.S.
- September 15, 2008
Thallion Presents Final Phase II TLN-232 Results in Advanced Kidney Cancer Patients at the ESMO Congress
- July 10, 2008
Thallion Announces 2008 Second Quarter Results
- July 7, 2008
Notice of Thallion Pharmaceuticals Fiscal 2008 Second Quarter Conference Call
- June 26, 2008
Thallion receives health canada approval to initiate Phase II study for TLN-232 in metastatic melanoma patients- Company initiates Phase II study with its second oncology product -
- May 12, 2008
Thallion Receives Health Canada Approval to Initiate Phase II for TLN-4601 in Brain Cancer
- April 8, 2008
Thallion Announces 2008 First Quarter Results
- April 4, 2008
Notice of Thallion Pharmaceuticals Fiscal 2008 First Quarter Conference Call
- March 27, 2008
Thallion Provides Update on Shigamabs® Program
- March 26, 2008
Thallion Redeems All Outstanding Special Preferred Shares
- February 14, 2008
Thallion Announces 2007 Year End Results
- February 12, 2008
Thallion Agrees with FDA on a Path Forward for Shigamabs Development Program in the U.S.
- February 5, 2008
Thallion Completes Patient Enrollment in Phase II Trial for CAP-232
- January 17, 2008
Thallion Resolves Dispute with CAP-232 Licensor